Regression of Metastatic Non-Small Cell Lung Cancer with Low Molecular Weight Heparin

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Thromb Haemost 2002; 88(04): 686
DOI: 10.1055/s-0037-1613276

Letters to the Editor

Schattauer GmbH

James T. Loynes

²Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, Vermont, USA

,

Leo R. Zacharski

¹Department of Veterans Affairs Medical Center, White River Jct., Vermont, USA

,

James R. Rigas

²Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, Vermont, USA

Further Information

Received 20 May 2002

Accepted 22 May 2002

Publication Date:
09 December 2017 (online)

References
1 Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 10-23.

Article in Thieme Connect PubMed Google Scholar
2 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 2000; 342 (26) 1953-8.

Crossref PubMed Google Scholar
3 Zacharski LR, Ornstein DL, Mamourian AC. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000; 26 (Suppl. 01) 69-77.

Article in Thieme Connect PubMed Google Scholar